Filing excerpt
Cash flows used in financing activities from continuing operations for the six months ended June 30, 2026 primarily included $2,054 million for the repayment of senior notes, $322 million paid to repurchase ordinary shares and $282 million of cash transferred to Versigent related to the spin-off, partially offset by the $1,920 million cash dividend received from Versigent.